Merck Group, SpringWorks
Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Analysts have had mixed feelings about Merck in recent years, with concerns the company, like other big pharmaceuticals, ...
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback